RAMB - Julho 2016

iabetes

mellitus

childhood

emerging

condition

the

century

ssoc

ras

2016; 62(6):594-601

601

44.

Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC. Sustained b cell

apoptosis in patients with long-standing type 1 diabetes: indirect evidence

for islet regeneration? Diabetologia. 2005; 48(11):2221-8.

45. Gaglia JL, Guimaraes AR, Harisinghani M, Turvey SE, Jackson R, Benoist

C, et al. Noninvasive imaging of pancreatic islet inflammation in type 1A

diabetes patients. J Clin Invest. 2011; 121(1):442-5.

46. Campbell-Thompson M, Wasserfall C, Montgomery EL, Atkinson MA,

Kaddis JS. Pancreas organ weight in individuals with disease-associated

autoantibodies at risk for type 1 diabetes. JAMA. 2012; 308(22):2337-9.

47. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;

383(9911):69-82.

48.

Pugliese A, Yang M, Kusmarteva I, Heiple T, Vendrame F, Wasserfall C, et

al. The Juvenile Diabetes Research Foundation Network for Pancreatic

Organ Donors with Diabetes (nPOD) Program: goals, operational model

and emerging findings. Pediatr Diabetes. 2014; 15(1):1-9.

49. Atkinson MA, Bluestone JA, Eisenbarth GS, Hebrok M, Herold KC, Accili

D, et al. How does type 1 diabetes develop?: the notion of homicide or beta-

cell suicide revisited. Diabetes. 2011; 60(5):1370-9.

50.

von Herrath M, Sanda S, Herold K. Type 1 diabetes as a relapsing-remitting

disease? Nat Rev Immunol. 2007; 7(12):988-94.

51.

Bonifacio E, Ziegler AG. Advances in the prediction and natural history of

type 1 diabetes. Endocrinol Metab Clin North Am. 2010; 39(3):513-25.

52. Greenbaum CJ, Beam CA, Boulware D, Gitelman SE, Gottlieb PA, Herold

KC, et al.; Type 1 Diabetes TrialNet Study Group. Fall in C-peptide during

first 2 years from diagnosis: evidence of at least two distinct phases from

composite type 1 diabetes TrialNet data. Diabetes. 2012; 61(8):2066-73.

53.

Simmons KM, Michels AW. Type 1 diabetes: a predictable disease. World J

Diabetes. 2015; 6(3):380-90.

54.

Ziegler AG, Bonifacio E; BABYDIAB-BABYDIET Study Group. Age-related

islet autoantibody incidence in offspring of patients with type 1 diabetes.

Diabetologia. 2012; 55(7):1937-43.

55.

Parikka V, Näntö-Salonen K, Saarinen M, Simell T, Ilonen J, Hyöty H, et al.

Early seroconversion and rapidly increasing autoantibody concentrations

predict prepubertal manifestation of type 1 diabetes in children at genetic

risk. Diabetologia. 2012; 55(7):1926-36.

56.

Nokoff N, Rewers M. Pathogenesis of type 1 diabetes: lessons from natural

history studies of high-risk individuals. Ann N Y Acad Sci. 2013; 1281:1-15.

57.

Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A, et al.

Seroconversion to multiple islet autoantibodies and risk of progression to

diabetes in children. JAMA. 2013; 309(23):2473-9.

58.

Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, et al.

Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the

Endocrine Society, and the American Diabetes Association. Diabetes Care.

2015; 38(10):1964-74.

59. Gottlieb PA. What defines disease in an age of genetics and biomarkers?

Curr Opin Endocrinol Diabetes Obes. 2015; 22(4):296-9.

60.

Krischer JP; Type 1 Diabetes TrialNet Study Group. The use of intermediate

endpoints in the design of type 1 diabetes prevention trials. Diabetologia.

2013; 56(9):1919-24.

61. Couper JJ, Haller MJ, Ziegler A-G, Knip M, Ludvigsson J, Craig ME. Phases

of type 1 diabetes in children and adolescents. Pediatric Diabetes. 2014:

15(Suppl. 20):18-25.

62.

Della Manna T, Steinmetz L, Campos PR, Farhat SC, Schvartsman C,

Kuperman H, et al. Subcutaneous use of a fast-acting insulin analog: an

alternative treatment for pediatric patients with diabetic ketoacidosis.

Diabetes Care. 2005; 28(8):1856-61.

63. Wolfsdorf JI, Allgrove J, Craig ME, Edge J, Glaser N, Jain V, et al. ISPADClinical

Practice Consensus Guidelines 2014. Diabetic ketoacidosis and hyperglycemic

hyperosmolar state. Pediatric Diabetes. 2014; 15(Suppl 20):154-79.

64. Oram RA, Jones AG, Besser RE, Knight BA, Shields BM, Brown RJ, et al. The

majority of patients with long-duration type 1 diabetes are insulinmicrosecretors

and have functioning beta cells. Diabetologia. 2014; 57(1):187-91.

65.

Effect of intensive therapy on residual beta-cell function in patients with

type 1 diabetes in the diabetes control and complications trial. A randomized,

controlled trial. The Diabetes Control and Complications Trial Research

Group. Ann Intern Med. 1998; 128(7):517-23.

66.

Steffes MW, Sibley S, Jackson M, Thomas W. Beta cell function and the

development of diabetes-related complications in the diabetes control and

complications trial. Diabetes Care. 2003; 26(3):832-6.

67.

Diabetes Control and Complications Trial Research Group. The effect of

intensive treatment of diabetes on the development and progression of long-

term complications in insulin-dependent diabetes mellitus. N Engl J Med.

1993; 329(14):977-86.

68. WhiteNH,ClearyPA,DahmsW,GoldsteinD,MaloneJ,TamborlaneWV;Diabetes

ControlandComplicationsTrial(DCCT)/EpidemiologyofDiabetesInterventions

andComplications(EDIC)ResearchGroup.Beneficialeffectsof intensivetherapy

of diabetes during adolescence: outcomes after the conclusion of the diabetes

control and complications trial (DCCT). J Pediatr. 2001; 139(6):804-12.

69.

Stratton IM, Adler AI, Neil AW, Matthews DR, Manley SE, Cull CA, et al.;

UK Prospective Diabetes Study Group. Association of glycaemia with

macrovascular and microvascular complications of type 2 diabetes (UKPDS

35): prospective observational study. BMJ. 2000; 321:405-12.

70.

Rewers MJ, Pillay K, de Beaufort C, Craig ME, Hanas R, Acerini CL, Maahs

DM. Assessment and monitoring of glycemic control in children and

adolescents with diabetes. Pediatric Diabetes. 2014: 15(Suppl.20):102-14.

71. American Diabetes Association. 11. Children and adolescents. Diabetes Care.

2016; 39(Suppl.l):S86-93.

72.

Heller SR. Structured education in type 1 diabetes. Br J Diabetes Vasc Dis.

2009; 9(6):269-72.

73.

Donaghue KC, Wadwa RP, Dimeglio LA, Wong TY, Chiarelli F, Marcovecchio

ML, et al. Microvascular and macrovascular complications in children and

adolescents. Pediatric Diabetes. 2014; 15(Suppl.20):257-69.